Navigation Links
Nile Therapeutics Reports 2011 Third Quarter Financial Results
Date:11/14/2011

escribed under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission on March 14, 2011. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.NILE THERAPEUTICS, INC.

(A DEVELOPMENT STAGE COMPANY)

CONDENSED STATEMENTS OF OPERATIONS

(unaudited)Three Months Ended September 30,Nine Months Ended September 30,2011201020112010IncomeCollaboration income$
813,000$
-$
,159,000$
-Operating expenses:Research and development1,470,0911,148,6412,795,3543,517,822General and administrative499,273664,0951,597,8551,732,745Total operating expenses1,969,3641,812,7364,393,2095,250,567Loss from operations(1,156,364)(1,812,736)(3,234,209)(5,250,567)Other income (expense):Interest income1,8805,9544,91217,526Interest expense----Other income (expense)10,411(2,711)8,901(2,793)Total other income (expense)

12,2913,24313,81314,733Net loss$
(1,144,073)$
(1,809,493)$
(3,220,396)$
(5,235,834)Basic and diluted loss per share$
(0.03)$
(0.05)$
(0.09)$
(0.17)Weighted-average common shares outstanding

39,707,76434,563,07336,526,34631,338,963NILE THERAPEUTICS, INC.

(A DEVELOPMENT STAGE COMPANY)

CONDENSED BALANCE SHEETSSeptember 30, 2011December 31, 2010(unaudited)ASSETS Current assets Cash and cash equivalents

$
2,607,336$
3,378,155Prepaid expenses and other current assets

420,653219,095Total current assets

3,027,9893,597,250 Property and equipment, net  

10,88616,765 Other noncurrent assets

51,93851,938Total assets

$
3,090,813$
3,665,953 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts  payable

$
504,333$
332,380Accrued  expenses and other current liabilities
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Orexigen® Therapeutics Reports Third Quarter Financial Results
3. Silence Therapeutics Provides Corporate and Development Update
4. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
5. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
6. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
7. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
8. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
9. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
10. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
11. DLVR Therapeutics Inc. Raises Additional Capital Adding MaRS Innovation to Investor Base
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , ... rare disease therapeutics enterprise, announced today that rare disease ... company as vice president, research. Dr. McKew brings more ... key leadership positions at the National Institutes of Health, ... acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts to ...
(Date:10/20/2014)... 2014 Convey Computer , the ... from Iowa State University won first place in the ... Convey HC-2ex, the team’s solution achieved the highest overall ... the second place finisher. , Experts from all segments ... month long challenge, using a variety of design tools, ...
(Date:10/20/2014)... October 20, 2014 , A ... disorders and the delivery of care has revealed changing ... worrying inequalities in the provision of healthcare services across ... commissioned by United European Gastroenterology (UEG), have been announced ... public awareness of the burden of GI disorders across ...
(Date:10/20/2014)... N.J. (PRWEB) October 20, 2014 ... the Sidney Kimmel Cancer Center at Thomas Jefferson ... , Through the Strategic Alliance Partnership program, ... OncLive will collaborate to raise awareness of the ... treatment, and other projects. Clinicians and other health ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... (Nasdaq: ALSE ), today announced that on January ... "Agreement") with Robert Gipson for the private placement of 1,000,000 ... price of $1.00 per share. The financing resulted in ... the Agreement, Mr. Gipson agreed to the cancellation of a ...
... Antibody Therapeutics BETHESDA, Md., Jan. 13 ... a biopharmaceutical company developing novel, proprietary antibodies for ... today announced the publication of an article in ... revealing a novel signalling function of the epithelial ...
... address attendees regarding the implementation of Homeland Security Presidential ... on January 27-28, 2009 at the Sheraton National Hotel in Arlington, ... ... – General Victor E. Renuart, Jr., Commander, North American ...
Cached Biology Technology:Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 2Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 3Alseres Pharmaceuticals, Inc. Announces $1 Million Financing 4Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 2Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 3Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling 4DoD Leader to Address Presidential Biometrics Security Directive at NDIA Conference 2DoD Leader to Address Presidential Biometrics Security Directive at NDIA Conference 3
(Date:10/15/2014)... , Oct. 15, 2014 Sandata Technologies, ... home and community-based care, today announced it released ... Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™)  for ... a home health company founded in 1996 and ... . The study details the ...
(Date:10/15/2014)... ,Models of Life, is a non-traditional biophysics textbook and ... book is a journey of discovery into biological systems ... and biological regulation. It is about how our genes ... between the billions of cells in an organism. It ... between principles, which can be found on both large ...
(Date:10/15/2014)... an unexpected extent. The outbreak does not follow the ... a new disease dynamic in regions, where it has ... National Academy of Sciences Leopoldina, acatech – the German ... the German Academies of Sciences and Humanities have presented ... the statement the academies call for the following consequences ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2New book about life as seen from physics 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... (Nasdaq: CALP) and Affymetrix, Inc. (Nasdaq: AFFX) today ... license to use a portion of Caliper's microfluidics ... license extends to the manufacture and sale of ... including research, diagnostics and applied genomics applications. In ...
... fungus perceives light also plays an important role in ... at Duke University Medical Center. The findings suggest that ... body may be an important and previously overlooked cue ... in the human pathogen Cryptococcus neoformans further suggests that ...
... cells make new proteins, may be more versatile and ... from the University of Michigan Medical School and the ... this same signaling protein is required for the formation ... a unique signaling pathway," says Randal Kaufman, Ph.D., a ...
Cached Biology News:Affymetrix Licenses Microfluidics Technology From Caliper Life Sciences 2Light therapy may combat fungal infections, new evidence suggests 2Light therapy may combat fungal infections, new evidence suggests 3Multi-purpose protein regulates new protein synthesis and immune cell development 2Multi-purpose protein regulates new protein synthesis and immune cell development 3
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
Biology Products: